v3.25.2
Equity Incentive Plans (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jan. 20, 2017
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Jul. 02, 2024
Jun. 16, 2023
Jun. 16, 2022
Options                  
Outstanding balance at the beginning of the period (in shares)       6,416,744          
Granted (in shares)       0          
Exercised (in shares)       (6,667)          
Forfeited (in shares)       (1,378,104)          
Outstanding balance at the end of the period (in shares)   5,031,973   5,031,973   6,416,744      
Options exercisable at the end of the period (in shares)   3,639,701   3,639,701          
Options vested and expected to vest at end of period (in shares)   5,031,973   5,031,973          
Weighted Average Exercise Price Per Share                  
Outstanding balance at the beginning of the period (in dollars per share)       $ 8.43          
Exercised (in dollars per share)       2.4          
Forfeited (in dollars per share)       7.55          
Outstanding balance at the end of the period (in dollars per share)   $ 8.68   8.68   $ 8.43      
Options exercisable at the end of the period (in dollars per share)   10.98   10.98          
Options vested and expected to vest at end of the period (in dollars per share)   $ 8.68   $ 8.68          
Weighted Average Remaining Life in Years                  
Outstanding balance       6 years   8 years 5 months 4 days      
Options exercisable at end of period       4 years 11 months 8 days          
Options vested and expected to vest at end of the period       6 years          
Aggregate Intrinsic Value                  
Outstanding balance           $ 1,937      
Assumptions used to determine grant-date fair value                  
Expected volatility         92.84%        
Weighted average risk-free interest rate         4.00%        
Expected dividend yield       0.00% 0.00%        
Expected term (in years)         6 years 5 months 8 days        
Expiration period       10 years          
Unrecognized compensation cost related to non-vested stock options   $ 2,205   $ 2,205          
Weighted average period for recognition of compensation cost       1 year 6 months 14 days          
Minimum                  
Assumptions used to determine grant-date fair value                  
Vesting period       3 years          
Maximum                  
Assumptions used to determine grant-date fair value                  
Vesting period       4 years          
Options to purchase common stock                  
Weighted Average Exercise Price Per Share                  
Granted (in dollars per share)         $ 2.12        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                  
Stock Based Compensation Expense   1,489 $ 1,370 $ 2,693 $ 2,618        
Options to purchase common stock | Research and development                  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                  
Stock Based Compensation Expense   387 729 1,021 1,356        
Options to purchase common stock | General and administrative                  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                  
Stock Based Compensation Expense   476 $ 641 1,046 $ 1,262        
Options to purchase common stock | Restructuring charges                  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                  
Stock Based Compensation Expense   $ 626   $ 626          
Restricted stock units to purchase common stock                  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]                  
Vested (in shares)       (220,000)          
Outstanding at the end   0   0          
2016 Plan                  
Assumptions used to determine grant-date fair value                  
Annual increase in authorized shares (as a percent) 4.00%                
2016 Plan | Restricted stock units to purchase common stock                  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]                  
Outstanding at the beginning       220,000          
Vested (in shares)       (220,000)          
Outstanding at the end           220,000      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                  
Outstanding at beginning( in dollars per share)       $ 19.4          
Vested(in dollars per share)       $ 19.4          
Outstanding at end(in dollars per share)           $ 19.4      
2022 Plan                  
Assumptions used to determine grant-date fair value                  
Number of options or stock awards available for grant under the Plan                 750,000
Common shares reserved for issuance             2,000,000 2,250,000  
2016 and 2022 Plan                  
Assumptions used to determine grant-date fair value                  
Number of options or stock awards available for grant under the Plan   3,922,812   3,922,812